SEC Form 4: Sullivan Eddie Joe was granted 5,216,564 shares

$BCYP
Finance
Get the next $BCYP alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Sullivan Eddie Joe

(Last) (First) (Middle)
2100 E 54TH STREET NORTH

(Street)
SIOUX FALLS SD 57104

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SAB Biotherapeutics, Inc. [ SABS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/07/2021
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/22/2021 A 5,213,764 A (1) 5,213,764 D
Common Stock 10/07/2021(2) A 2,800 A $10.07 2,800 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Earnout Rights (Common Stock) (3)(4) 10/22/2021 A 2,106,361 (3)(4) (3) Common Stock 2,106,361 (3)(4) 2,106,361 D
Employee Stock Option (right to buy) $0.25 10/22/2021 A 139,585 (5)(6) 08/05/2024 Common Stock 139,585 (5)(6) 139,585 D
Employee Stock Option (right to buy) $0.25 10/22/2021 A 162,850 (5)(6) 12/12/2024 Common Stock 162,850 (5)(6) 162,850 D
Employee Stock Option (right to buy) $0.25 10/22/2021 A 162,850 (5)(6) 12/12/2024 Common Stock 162,850 (5)(6) 162,850 D
Employee Stock Option (right to buy) $1.25 10/22/2021 A 23,264 (5)(6) 04/27/2030 Common Stock 23,264 (5)(6) 23,264 D
Restricted Stock Unit (7) 10/22/2021 A 197,374 (7) (3) Common Stock 197,374 (7) 197,374 D
Explanation of Responses:
1. Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each share of Old SAB Biotherapeutics issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer").
2. This transaction occurred prior to the business combination. The reporting person's obligation to disclose this transaction occurred upon the consummation of the business combination.
3. Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]
4. 25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period.
5. Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.
6. The option is fully vested.
7. In connection with the business combination, the reporting person received additional New SAB Biotherapeutics restricted stock units, or RSUs, where each RSU represents a contingent right to receive one share of common stock (the "Earnout RSUs"). The Earnout RSUs will be released upon the same milestones as the Earnout Shares.
/s/ Eddie Joe Sullivan 10/26/2021
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $BCYP alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BCYP

DatePrice TargetRatingAnalyst
10/4/2021$18.00Outperform
Northland Capital Markets
10/1/2021$16.50Buy
Ladenburg Thalmann
More analyst ratings

$BCYP
Press Releases

Fastest customizable press release news feed in the world

See more
  • SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company

    Completed Business Combination with Big Cypress Acquisition Corp. Common stock to commence trading on the Nasdaq Global Market October 25, 2021, under the ticker symbol "SABS" SIOUX FALLS, S.D., Oct. 25, 2021 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ:SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the completion of its business combination with Big Cypress Acquisition Corp. (NASDAQ:BCYP) ("Big Cypress"), a publicly-traded special purpose acquisition company (SPAC) focused on innovative biopharmaceutical

    $BCYP
    Finance
  • Big Cypress Acquisition Corp. Stockholders Approve Business Combination with SAB Biotherapeutics

    MIAMI, Oct. 21, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp. (NASDAQ:BCYP), (Big Cypress) a publicly-traded special purpose acquisition company focused on innovative biopharmaceutical firms, today announced that its stockholders have approved the proposed business combination (the "Business Combination") with SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform producing targeted, high potency, fully-human polyclonal antibody therapeutics and advancing programs in infectious disease and immune system disorders, at a Special Meeting of stockholders held on October 20, 2021 (the "Special Meeting"). Approximately 98.3% of t

    $BCYP
    Finance
  • SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021

    SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that it will host a virtual R&D Day on Wednesday, October 13, 2021, at 10:00 a.m. ET to showcase its versatile DiversitAb™ platform and pipeline of clinical and preclinical programs. The event will feature SAB management and key opinion leaders, including: Arturo Casadevall, MD, PhD – The Alfred and Jill Sommer Professor and Chair, W. Harry Feinstone Department of Molecular Microbiology & Immunology, Bloomberg Distinguished Professor, Johns Hopkins B

    $BCYP
    Finance

$BCYP
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$BCYP
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$BCYP
Leadership Updates

Live Leadership Updates

See more
  • SAB Biotherapeutics Appoints Russell Beyer Chief Financial Officer

    SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the appointment of Russell Beyer as chief financial officer (CFO), effective September 20, 2021. Mr. Beyer will lead all aspects of SAB's financial operations and key supporting functions and will work with the senior management team to drive SAB's growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928005435/en/(Photo: Business Wire) "We welcome Russell to the SAB team at an exciting t

    $BCYP
    Finance

$BCYP
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more